 |
[Apha Biz=(Chicago) Reporter Paul Lee] More than 200 patients receive free supply of Yuhan Corp.'s new non-small cell lung cancer drug "LECLAZA," which costs about 75 million won a year to take.
In other words, Yuhan Corp. provides more than 1.28 billion won worth of medicine free of charge to more than 200 patients each month.
Yuhan Corporation's LECLAZA free supply is the primary treatment for lung cancer until health insurance benefits are applied. LECLAZA's salary is expected to be listed as early as next year.
According to the pharmaceutical industry on the 13th, more than 200 patients participated in the "Early Supply Program (EAP)" operated by Yuhan Corp. in July to supply LECLAZA free of charge as a primary treatment for non-small cell lung cancer. The record came less than two months after the first free prescription patient came out in July.
Considering that the price of the LECLAZA 80㎎ 1 tablet is 68,964 won and 206,892 won per day if insurance is not applied, the price of the medicine is about 6.4 million won per month and 75 million won per year. In other words, Yuhan Corporation will provide this free of charge to more than 200 people.
Yuhan Corp. previously pushed for the application of benefits after LECLAZA was approved by the Ministry of Food and Drug Safety as the primary treatment for epithelial cell growth factor receptor (EGFR) mutation positive non-small cell lung cancer in June. In the meantime, patients were allowed to take LECLAZA free of charge until they were listed as health insurance benefits as the primary treatment.
Alphabiz Reporter Paul Lee(hoondork1977@alphabiz.co.kr)
